These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8473090)

  • 21. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
    Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
    Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combined hormone and chemotherapy for the patients with advanced prostate cancer].
    Uekado Y; Hirano A; Inagaki T; Hiroi A; Watanabe T
    Gan To Kagaku Ryoho; 1995 Jul; 22(8):1041-5. PubMed ID: 7611755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate: Mayo Clinic experience.
    Zincke H
    Semin Urol; 1990 Aug; 8(3):175-83. PubMed ID: 2399386
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H; Lau W; Bergstralh E; Blute ML
    J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of clinically localized prostatic cancer--endocrine therapy].
    Hirano A
    Hinyokika Kiyo; 1996 Oct; 42(10):829-32. PubMed ID: 8951483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combination hormone-chemotherapy versus hormone therapy alone in the initial treatment of advanced prostate carcinoma--a prospective cooperative study].
    Gorski J; Böhm WD; Illig HD; Koch R
    Urologe A; 1988 Sep; 27(5):287-90. PubMed ID: 3051628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined androgen blockade in the management of advanced prostate cancer: a sensible or ostensible approach.
    Ansari MS; Gupta NP; Hemal AK; Dogra PN; Seth A
    Int J Urol; 2004 Dec; 11(12):1092-6. PubMed ID: 15663681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neoadjuvant endocrine therapy in patients with locally advanced prostate cancer].
    Maeda O; Meguro N; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
    Hinyokika Kiyo; 1996 Oct; 42(10):821-7. PubMed ID: 8951482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reasons for delay of endocrine treatment in cancer of the prostate (until symptomatic metastases occur).
    Christensen MM; Aagaard J; Madsen PO
    Prog Clin Biol Res; 1990; 359():7-14; discussion 15-24. PubMed ID: 2284298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
    Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical analysis of 169 patients with prostate cancer].
    Okaneya T; Mizusawa H; Yoneyama T; Taguchi I; Komiyama I; Kawakami M; Hosaka K; Tsuruta T; Murata Y; Komatsu H; Misawa K; Kiyokawa H
    Hinyokika Kiyo; 1996 Aug; 42(8):563-7. PubMed ID: 8889563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update].
    Drouin SJ; Rouprêt M; Davin JL; Soulié M
    Prog Urol; 2009 Apr; 19 Suppl 1():S15-9. PubMed ID: 19465332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring of prostate volume by ultrasound in hormonally treated prostate cancer.
    Brandt B; Menu G; el Khansa A; Lardennois B
    Prog Clin Biol Res; 1987; 243B():13-9. PubMed ID: 3309979
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of competing risk parameters in irradiated prostate cancer patients.
    Mayer R; Pummer K; Quehenberger F; Mayer E; Feigl G; Langsenlehner U; Hackl A
    Strahlenther Onkol; 2003 Jul; 179(7):452-7. PubMed ID: 12835881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2009 Mar; 181(3):1091-7. PubMed ID: 19150091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.